Coxsackie B and adenovirus receptor, integrin and major histocompatibility complex class I expression in human prostate cancer cell lines: implications for gene therapy strategies

H S Pandha, L H Stockwin, J Eaton, I A Clarke, A G Dalgleish, S M Todryk, G E Blair

    Research output: Contribution to journalArticle

    21 Citations (Scopus)

    Abstract

    Gene therapy strategies based on modifying tumour cells using high efficiency adenoviral vectors have shown promise in the clinic. Recently the Coxsackie and adenovirus receptor (CAR) has been shown to mediate adenoviral entry into tumour cells, although previous studies also suggested a role for MHC class I heavy chain. Detailed evaluation of the expression of both CAR and MHC class I in prostate cancer cell lines would have important implications for therapeutic strategies. We have found that, unlike cell lines derived from other malignancies, in human and murine prostate cancer loss of CAR expression appears to be relatively infrequent and does not correlate with loss of MHC class I expression. These findings, together with the demonstration of appreciable levels of cell-surface expression of integrins, suggest that cancer vaccine strategies based on modifying whole prostate cancer cells should be feasible using the current generation of recombinant adenoviral vectors, without deleterious effects on either the virus vector or the target cell.
    Original languageEnglish
    Pages (from-to)6-11
    Number of pages6
    JournalProstate Cancer and Prostatic Diseases
    Volume6
    Issue number1
    DOIs
    Publication statusPublished - 2003

    Fingerprint

    Coxsackie and Adenovirus Receptor-Like Membrane Protein
    Major Histocompatibility Complex
    Integrins
    Genetic Therapy
    Prostatic Neoplasms
    Cell Line
    Neoplasms
    Cancer Vaccines
    Viruses

    Cite this

    Coxsackie B and adenovirus receptor, integrin and major histocompatibility complex class I expression in human prostate cancer cell lines : implications for gene therapy strategies. / Pandha, H S; Stockwin, L H; Eaton, J; Clarke, I A; Dalgleish, A G; Todryk, S M; Blair, G E.

    In: Prostate Cancer and Prostatic Diseases, Vol. 6, No. 1, 2003, p. 6-11.

    Research output: Contribution to journalArticle

    @article{eb5553263b8f445981ac16845a28bcb4,
    title = "Coxsackie B and adenovirus receptor, integrin and major histocompatibility complex class I expression in human prostate cancer cell lines: implications for gene therapy strategies",
    abstract = "Gene therapy strategies based on modifying tumour cells using high efficiency adenoviral vectors have shown promise in the clinic. Recently the Coxsackie and adenovirus receptor (CAR) has been shown to mediate adenoviral entry into tumour cells, although previous studies also suggested a role for MHC class I heavy chain. Detailed evaluation of the expression of both CAR and MHC class I in prostate cancer cell lines would have important implications for therapeutic strategies. We have found that, unlike cell lines derived from other malignancies, in human and murine prostate cancer loss of CAR expression appears to be relatively infrequent and does not correlate with loss of MHC class I expression. These findings, together with the demonstration of appreciable levels of cell-surface expression of integrins, suggest that cancer vaccine strategies based on modifying whole prostate cancer cells should be feasible using the current generation of recombinant adenoviral vectors, without deleterious effects on either the virus vector or the target cell.",
    author = "Pandha, {H S} and Stockwin, {L H} and J Eaton and Clarke, {I A} and Dalgleish, {A G} and Todryk, {S M} and Blair, {G E}",
    year = "2003",
    doi = "10.1038/sj.pcan.4500611",
    language = "English",
    volume = "6",
    pages = "6--11",
    journal = "Prostate Cancer and Prostatic Diseases",
    issn = "1365-7852",
    publisher = "Nature Publishing Group",
    number = "1",

    }

    TY - JOUR

    T1 - Coxsackie B and adenovirus receptor, integrin and major histocompatibility complex class I expression in human prostate cancer cell lines

    T2 - implications for gene therapy strategies

    AU - Pandha, H S

    AU - Stockwin, L H

    AU - Eaton, J

    AU - Clarke, I A

    AU - Dalgleish, A G

    AU - Todryk, S M

    AU - Blair, G E

    PY - 2003

    Y1 - 2003

    N2 - Gene therapy strategies based on modifying tumour cells using high efficiency adenoviral vectors have shown promise in the clinic. Recently the Coxsackie and adenovirus receptor (CAR) has been shown to mediate adenoviral entry into tumour cells, although previous studies also suggested a role for MHC class I heavy chain. Detailed evaluation of the expression of both CAR and MHC class I in prostate cancer cell lines would have important implications for therapeutic strategies. We have found that, unlike cell lines derived from other malignancies, in human and murine prostate cancer loss of CAR expression appears to be relatively infrequent and does not correlate with loss of MHC class I expression. These findings, together with the demonstration of appreciable levels of cell-surface expression of integrins, suggest that cancer vaccine strategies based on modifying whole prostate cancer cells should be feasible using the current generation of recombinant adenoviral vectors, without deleterious effects on either the virus vector or the target cell.

    AB - Gene therapy strategies based on modifying tumour cells using high efficiency adenoviral vectors have shown promise in the clinic. Recently the Coxsackie and adenovirus receptor (CAR) has been shown to mediate adenoviral entry into tumour cells, although previous studies also suggested a role for MHC class I heavy chain. Detailed evaluation of the expression of both CAR and MHC class I in prostate cancer cell lines would have important implications for therapeutic strategies. We have found that, unlike cell lines derived from other malignancies, in human and murine prostate cancer loss of CAR expression appears to be relatively infrequent and does not correlate with loss of MHC class I expression. These findings, together with the demonstration of appreciable levels of cell-surface expression of integrins, suggest that cancer vaccine strategies based on modifying whole prostate cancer cells should be feasible using the current generation of recombinant adenoviral vectors, without deleterious effects on either the virus vector or the target cell.

    U2 - 10.1038/sj.pcan.4500611

    DO - 10.1038/sj.pcan.4500611

    M3 - Article

    C2 - 12664058

    VL - 6

    SP - 6

    EP - 11

    JO - Prostate Cancer and Prostatic Diseases

    JF - Prostate Cancer and Prostatic Diseases

    SN - 1365-7852

    IS - 1

    ER -